287 related articles for article (PubMed ID: 17057271)
1. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
de Langen JJ; van Puijenbroek EP
Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
[TBL] [Abstract][Full Text] [Related]
2. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
Fraunfelder FW; Richards AB
Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
[TBL] [Abstract][Full Text] [Related]
3. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
de Graaf L; Brouwers AH; Diemont WL
Br J Clin Pharmacol; 2004 Sep; 58(3):326-8. PubMed ID: 15327593
[TBL] [Abstract][Full Text] [Related]
4. Peripheral neuropathy and statins.
Prescrire Int; 2007 Dec; 16(92):247-8. PubMed ID: 18092417
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin-induced lactic acidosis: a rare adverse reaction?
Goli AK; Goli SA; Byrd RP; Roy TM
Clin Pharmacol Ther; 2002 Oct; 72(4):461-4. PubMed ID: 12386648
[TBL] [Abstract][Full Text] [Related]
6. Association of HMG-CoA reductase inhibitors with neuropathy.
Backes JM; Howard PA
Ann Pharmacother; 2003 Feb; 37(2):274-8. PubMed ID: 12549960
[TBL] [Abstract][Full Text] [Related]
7. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
Sparing R; Sellhaus B; Noth J; Block F
Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
[TBL] [Abstract][Full Text] [Related]
8. Statin safety: an appraisal from the adverse event reporting system.
Davidson MH; Clark JA; Glass LM; Kanumalla A
Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitors and myotoxicity.
Ucar M; Mjörndal T; Dahlqvist R
Drug Saf; 2000 Jun; 22(6):441-57. PubMed ID: 10877038
[TBL] [Abstract][Full Text] [Related]
10. [Statins--the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database].
Buajordet I; Madsen S; Olsen H
Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3210-3. PubMed ID: 9411859
[TBL] [Abstract][Full Text] [Related]
11. [Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase].
Fuentes I; Aguilera C
Med Clin (Barc); 1998 Nov; 111(18):700. PubMed ID: 9887435
[No Abstract] [Full Text] [Related]
12. HMG-CoA reductase inhibitors in organ transplantation.
Motomura N; Saito S; Foegh ML
J Nephrol; 1997; 10(2):68-76. PubMed ID: 9238613
[TBL] [Abstract][Full Text] [Related]
13. HMG-CoA reductase inhibition: the start of a new age in the treatment of hypercholesterolaemia.
Meinders AE
Neth J Med; 1988 Jun; 32(5-6):213-6. PubMed ID: 3292961
[No Abstract] [Full Text] [Related]
14. Statin-associated peripheral neuropathy: review of the literature.
Chong PH; Boskovich A; Stevkovic N; Bartt RE
Pharmacotherapy; 2004 Sep; 24(9):1194-203. PubMed ID: 15460180
[TBL] [Abstract][Full Text] [Related]
15. [Transplant coronary artery disease--treatment with statins].
Wolszakiewicz J; Bilińska M
Pol Merkur Lekarski; 2004 May; 16(95):472-3. PubMed ID: 15518430
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
[TBL] [Abstract][Full Text] [Related]
17. Neuromuscular complications of statins.
Ahn SC
Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):47-59, vi. PubMed ID: 18194749
[TBL] [Abstract][Full Text] [Related]
18. [The selection of a drug in a defined therapeutic class: the case of the HMG-CoA reductase inhibitors].
Girardin F; Desmeules J; Dayer P
Rev Med Suisse; 2005 Apr; 1(14):949-53. PubMed ID: 15898679
[TBL] [Abstract][Full Text] [Related]
19. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
da Silva VB; Taft CA; Silva CH
J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
[TBL] [Abstract][Full Text] [Related]
20. [Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase].
Martinez-García FA; Martín-Fernández J; Moltó JM; Villaverde R; Morales A; Fernández-Barreiro A
Rev Neurol; 1997 Jun; 25(142):869-71. PubMed ID: 9244616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
